<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515838</url>
  </required_header>
  <id_info>
    <org_study_id>TVOC01</org_study_id>
    <nct_id>NCT02515838</nct_id>
  </id_info>
  <brief_title>Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD</brief_title>
  <official_title>A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects With Sickle-Cell Disease (SCD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Modus Therapeutics AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ergomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Modus Therapeutics AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to investigate
      Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis
      (VOC) in Subjects with Sickle-Cell Disease (SCD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a phase II, multi-centre, randomized, double-blind, placebo-controlled study
      designed to assess preliminary efficacy, safety and pharmacokinetics (PK) of 2-7 days
      continuous IV administration of sevuparin for the management of acute VOC in subjects with
      SCD.

      Adults and adolescents ≥ 12 years of age will be randomized to treatment with sevuparin or
      placebo (ratio 1:1).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to resolution of VOC</measure>
    <time_frame>From hospitalisation until discharge, defined as freedom from parenteral opioid use and readiness for discharge i.e. from randomisation until day 7</time_frame>
    <description>Time from start of infusion until resolution of VOC crisis/episode</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and pattern of treatment-emergent adverse event (TEAEs)</measure>
    <time_frame>Time from start randomsiation until end of study, approximately 1 month 1 week after randomisation</time_frame>
    <description>All events to be reported from randomization until end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) characteristics of sevuparin</measure>
    <time_frame>Pre dose, 1h, 2h, 24h, 1/day (day 3-8)</time_frame>
    <description>PK characteristics of sevuparin during and after administration of sevuparin as a continuous IV infusion (subgroup) ◦Area under the plasma concentration versus time curve (AUC) of Sevuparin.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">133</enrollment>
  <condition>Sickle-Cell Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevuparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevuparin infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevuparin</intervention_name>
    <description>The Drug Product sevuparin solution for IV infusion</description>
    <arm_group_label>Sevuparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign a written informed consent (adults, parents) and assent (adolescents)

          -  Male or female, age 12-50 years.

          -  Diagnosis of Sickle cell disease

          -  Subjects admitted for an acute, painful VOC to be treated/or treated with parenteral
             opioid analgesia.

          -  Expectancy of need for hospitalization during at least 48 hours.

          -  Be at least 1 year postmenopausal, surgically sterile, or if Women of Child Bearing
             Potential (WOCBP), e.g. following menarche practicing an effective method of birth
             control

        Exclusion Criteria:

          -  Severe hepatic failure/disease, abnormal liver enzyme tests or history of hepatitis B
             virus (HBV), hepatitis C virus (HCV)

          -  Abnormal conjugated (direct) bilirubin 3 fold above ULN

          -  History of clinically significant bleeding in vital organs

          -  Current clinically significant bleeding, as judged by the investigator

          -  Current use of acetylsalicylic acid (ASA), anti-platelet therapy, anticoagulant
             therapy

          -  Abnormal coagulation laboratory values

          -  A platelet count &lt;75,000/µL.

          -  BMI &gt;35

          -  Subjects with more than 5 hospitalizations for VOC during the last 6 months

          -  Evidence of acute SCD complications other than VOC at screening

          -  The use of strong opioids for &gt; 3 consecutive days during the last 15 days before
             presenting to the hospital

          -  History of chronic drug abuse.

          -  Renal dysfunction

          -  Known infection (positivity) with human immunodeficiency virus (HIV), HBV or HCV.

          -  Significant ECG abnormality

          -  History of a clinically significant drug allergy to heparin, LMWH's, sevuparin, or
             morphine.

          -  Use of any investigational agent during the 30 days prior to the first dose.

          -  For females: pregnancy, lactating or intention of becoming pregnant

          -  Evidence of clinically significant disorders that might interfere with the study aim
             or safety of the subject

          -  Any condition that, in the view of the Investigator, places the subject at high risk
             of poor treatment compliance or of not completing the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Bart J Biemond, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Bart J Biemond, MD, PhD</last_name>
    <email>b.j.biemond@amc.uva.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Salmaniya Hospital, Kingdom of Bahrain</name>
      <address>
        <city>Manama</city>
        <country>Bahrain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Najat Mahdi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salmaniya Medical Complex, Bahrain</name>
      <address>
        <city>Manama</city>
        <country>Bahrain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Mohamed Hassan Nafea, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annotto Bay Hospital</name>
      <address>
        <city>Annotto Bay</city>
        <country>Jamaica</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Kingston Public Hospital</name>
      <address>
        <city>Kingston</city>
        <country>Jamaica</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of the West Indies</name>
      <address>
        <city>Kingston</city>
        <country>Jamaica</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Winchester Surgical and Medical Institute</name>
      <address>
        <city>Kingston</city>
        <country>Jamaica</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mandeville Regional Hospital</name>
      <address>
        <city>Mandeville</city>
        <country>Jamaica</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>May Pen Public Hospital Clarendon</name>
      <address>
        <city>May Pen</city>
        <country>Jamaica</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cornwall Regional Hospital, Jamaica</name>
      <address>
        <city>Montego Bay</city>
        <country>Jamaica</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>American University of Beirut Medical Center, Beirut, Cairo street, Beirut, Lebanon</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Miguel Abboud, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nini Hospital</name>
      <address>
        <city>Tripoli</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Adlette Inati, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of Haematology</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Bart J Biemond, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sultan Qaboos University Hospital Alkhodh, Oman</name>
      <address>
        <city>Muscat</city>
        <country>Oman</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Yasser Wali, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sultan Qaboos University</name>
      <address>
        <city>Muscat</city>
        <country>Oman</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Murtadha Al-Khabori , MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Fahd Medical City, As Sulimaniyah, Riyadh Saudiarabien</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alaa Morsi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Saud University, Riyadh, Saudiarabien</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahman Al Sultan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mersin University Faculty of Medicine</name>
      <address>
        <city>Adana</city>
        <state>Mersin</state>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Anıl Tombak, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cukurova University Faculty Of Medicine Tıp Fakültesi</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Yurdanur Kilinc, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Antmen</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Antmen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bahrain</country>
    <country>Jamaica</country>
    <country>Lebanon</country>
    <country>Netherlands</country>
    <country>Oman</country>
    <country>Saudi Arabia</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

